FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522542987> ?p ?o ?g. }

• W2522542987 abstract "Abstract Abstract 2242 The relevance of factor IXa as a therapeutic target for heparin therapy remains incompletely defined. To evaluate the contribution of factor IXa inhibition, particularly serpin-independent inhibition of the intrinsic tenase complex (factor IXa-factor VIIIa), the ability of heparin preparations to inhibit tissue factor (TF)-triggered thrombin generation was examined in human plasma. Thrombin generation was determined by a fluorogenic substrate assay employing Technothrombin TGA evaluation software to determine lag time, time to thrombin peak, peak thrombin concentration, and velocity index (slope). The inhibitory potency (EC50) of each heparin was determined by plotting concentration versus relative velocity index (ratio of the velocity index in presence and absence of heparin). Inhibition of thrombin generation was initially compared under factor IX-dependent (limiting TF) and independent (excess TF) conditions, respectively, by addition of either 0.2 or 4 pM TF to pooled normal human plasma containing increasing concentrations of low molecular weight heparin (LMWH), super-sulfated LMWH (ssLMWH), Fondaparinux, or unfractionated heparin (UFH). UFH and Fondaparinux demonstrated complete or near complete inhibition with identical EC50 values at both tissue factor concentrations, suggesting that inhibition of intrinsic tenase activity does not significantly contribute to their mechanism of action in plasma. In contrast, LMWH and ssLMWH demonstrated 2.9- and 5.1-fold lower EC50 values, respectively, in the presence of the limiting TF concentration. These results suggest that inhibition of intrinsic tenase activity contributes to the mechanism of action for LMWH in plasma. The effect of heparins on the time course of plasma thrombin generation by Western blotting under similar conditions correlated well with results of the fluorogenic substrate assay. At their EC50 values, LMWH, ssLMWH and Fondaparinux clearly reduced prothrombin/meizothrombin consumption in plasma, while UFH primarily accelerated formation of the thrombin-antithrombin complex. The contribution of antithrombin to inhibition of thrombin generation was determined by comparison of antithrombin- and mock-depleted human plasmas. As expected, antithrombin depletion markedly increased the EC50 values for UFH (62–fold) and Fondaparinux (42-fold) to levels that are ∼3–8 fold higher than their expected therapeutic ranges, confirming an antithrombin-dependent mechanism of action. In contrast, antithrombin depletion increased the EC50 values more modestly for LMWH (9.4-fold) and ssLMWH (2-fold), with the EC50 for LMWH (∼ 0.7 U/ml) remaining within the therapeutic range. In the absence of antithrombin, LMWH demonstrated partial inhibition of plasma thrombin generation with a plateau representing ∼8–10% of the starting activity, remarkably similar to the inhibition of intrinsic tenase activity with purified components. The molecular target for LMWH and ssLMWH was evaluated in dual factor IX/antithrombin-depleted plasma supplemented with 90 nM recombinant factor IX possessing mutations in the heparin-binding exosite. Based on both relative EC50 values for reduction in the velocity index and the maximal degree of inhibition, plasma supplemented with mutant factor IX demonstrated relative resistance to inhibition of thrombin generation by LMWH as follows: R233A > (K126A/R165A/K132A) > R170A > WT. Factor IX R233A demonstrated an 11.4-fold increase in the EC50 for LMWH relative to the wild type protease. The magnitude of differences between mutant factor IX proteins was reduced for ssLMWH relative to LMWH, but the rank order was similar. The effect of these mutations in human plasma recapitulates their effects on in vitro inhibition of intrinsic tenase activity, confirming the factor IXa heparin-binding exosite as the molecular target for antithrombin-independent inhibition of thrombin generation by LMWH and ssLMWH. The ability of therapeutic concentrations of LMWH to directly target factor IXa in antithrombin-depleted plasma suggests that this mechanism may contribute to antithrombotic effects. Furthermore, chemo-enzymatic synthesis of “non-anticoagulant” LMWH preparations acting via this exosite-mediated antithrombotic mechanism may offer advantages in high-risk populations, particularly patients with underlying malignancy. Disclosures: Buyue: Biogen Idec Hemophilia: Employment." @default.
• W2522542987 created "2016-09-30" @default.
• W2522542987 creator A5025672145 @default.
• W2522542987 creator A5046167047 @default.
• W2522542987 date "2011-11-18" @default.
• W2522542987 modified "2023-09-29" @default.
• W2522542987 title "Low Molecular Weight Heparin Inhibits Plasma Thrombin Generation Via Direct Targeting of Factor IXa: Contribution of the Serpin-Independent Mechanism" @default.
• W2522542987 doi "https://doi.org/10.1182/blood.v118.21.2242.2242" @default.
• W2522542987 hasPublicationYear "2011" @default.
• W2522542987 type Work @default.
• W2522542987 sameAs 2522542987 @default.
• W2522542987 citedByCount "0" @default.
• W2522542987 crossrefType "journal-article" @default.
• W2522542987 hasAuthorship W2522542987A5025672145 @default.
• W2522542987 hasAuthorship W2522542987A5046167047 @default.
• W2522542987 hasBestOaLocation W25225429872 @default.
• W2522542987 hasConcept C104317684 @default.
• W2522542987 hasConcept C12554922 @default.
• W2522542987 hasConcept C126322002 @default.
• W2522542987 hasConcept C185592680 @default.
• W2522542987 hasConcept C186738567 @default.
• W2522542987 hasConcept C2776877702 @default.
• W2522542987 hasConcept C2776884760 @default.
• W2522542987 hasConcept C2777292125 @default.
• W2522542987 hasConcept C2777444498 @default.
• W2522542987 hasConcept C2777557582 @default.
• W2522542987 hasConcept C2778382381 @default.
• W2522542987 hasConcept C2778965386 @default.
• W2522542987 hasConcept C2780868729 @default.
• W2522542987 hasConcept C2910886357 @default.
• W2522542987 hasConcept C2991741193 @default.
• W2522542987 hasConcept C55493867 @default.
• W2522542987 hasConcept C71924100 @default.
• W2522542987 hasConcept C86803240 @default.
• W2522542987 hasConcept C89560881 @default.
• W2522542987 hasConcept C98274493 @default.
• W2522542987 hasConceptScore W2522542987C104317684 @default.
• W2522542987 hasConceptScore W2522542987C12554922 @default.
• W2522542987 hasConceptScore W2522542987C126322002 @default.
• W2522542987 hasConceptScore W2522542987C185592680 @default.
• W2522542987 hasConceptScore W2522542987C186738567 @default.
• W2522542987 hasConceptScore W2522542987C2776877702 @default.
• W2522542987 hasConceptScore W2522542987C2776884760 @default.
• W2522542987 hasConceptScore W2522542987C2777292125 @default.
• W2522542987 hasConceptScore W2522542987C2777444498 @default.
• W2522542987 hasConceptScore W2522542987C2777557582 @default.
• W2522542987 hasConceptScore W2522542987C2778382381 @default.
• W2522542987 hasConceptScore W2522542987C2778965386 @default.
• W2522542987 hasConceptScore W2522542987C2780868729 @default.
• W2522542987 hasConceptScore W2522542987C2910886357 @default.
• W2522542987 hasConceptScore W2522542987C2991741193 @default.
• W2522542987 hasConceptScore W2522542987C55493867 @default.
• W2522542987 hasConceptScore W2522542987C71924100 @default.
• W2522542987 hasConceptScore W2522542987C86803240 @default.
• W2522542987 hasConceptScore W2522542987C89560881 @default.
• W2522542987 hasConceptScore W2522542987C98274493 @default.
• W2522542987 hasLocation W25225429871 @default.
• W2522542987 hasLocation W25225429872 @default.
• W2522542987 hasOpenAccess W2522542987 @default.
• W2522542987 hasPrimaryLocation W25225429871 @default.
• W2522542987 hasRelatedWork W1489029649 @default.
• W2522542987 hasRelatedWork W1517218704 @default.
• W2522542987 hasRelatedWork W1570022137 @default.
• W2522542987 hasRelatedWork W1653001760 @default.
• W2522542987 hasRelatedWork W1967090971 @default.
• W2522542987 hasRelatedWork W1997412617 @default.
• W2522542987 hasRelatedWork W2027864189 @default.
• W2522542987 hasRelatedWork W2036765905 @default.
• W2522542987 hasRelatedWork W2036968552 @default.
• W2522542987 hasRelatedWork W2090440895 @default.
• W2522542987 hasRelatedWork W2150875473 @default.
• W2522542987 hasRelatedWork W2206994730 @default.
• W2522542987 hasRelatedWork W2418836298 @default.
• W2522542987 hasRelatedWork W2428106736 @default.
• W2522542987 hasRelatedWork W2510769589 @default.
• W2522542987 hasRelatedWork W2531607501 @default.
• W2522542987 hasRelatedWork W2593925045 @default.
• W2522542987 hasRelatedWork W2980241079 @default.
• W2522542987 hasRelatedWork W2994468470 @default.
• W2522542987 hasRelatedWork W3144615945 @default.
• W2522542987 isParatext "false" @default.
• W2522542987 isRetracted "false" @default.
• W2522542987 magId "2522542987" @default.
• W2522542987 workType "article" @default.